What are the main indications for pemetinib?

Pemigatinib is a highly potent and selective oral drug targeting FGFR (fibroblast growth factor receptor), specifically the FGFR1, FGFR2 and FGFR3 subtypes. It has shown significant efficacy in the treatment of FGFR1rearranged myeloid/lymphoid neoplasms and previously treated adults with locally advanced or metastatic unresectable cholangiocarcinoma.

Pemetinib inhibits the tyrosine kinase activity of FGFR1 and blocks the conduction of downstream signaling pathways, thereby inhibiting the proliferation and survival of tumor cells carrying FGFR1 rearrangement mutations. This mechanism provides new treatment options for patients with lymphoid tumors, especially those who are resistant to traditional chemotherapy drugs. Multiple studies have shown that pemetinib exhibits good efficacy in the treatment of relapsed or refractory lymphoid tumors with FGFR1 rearrangements. For example, in some clinical trials, monotherapy with pemetinib resulted in significant tumor shrinkage and prolonged survival in some patients.

Pemetinib prevents the growth and spread of tumor cells by blocking FGFR2 in tumor cells. This is particularly important for patients with cholangiocarcinoma who have FGFR2 fusions or rearrangements, as these tumors are often insensitive to traditional chemotherapy drugs.

In clinical trials such as the FIGHT-202 study, pemetinib has shown significant efficacy in the treatment of previously treated patients with locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. Among all patients who received second-line pemetinib, 38 patients (35.5%) experienced objective responses, including 3 complete responses and 35 partial responses. The median progression-free survival (mPFS) was 6.9 months, and the median overall survival (mOS) is as high as 21.1 months, far exceeding the survival time of the current gold standard regimen of first-line systemic chemotherapy for intrahepatic cholangiocarcinoma (11.7 months).

Although some adverse reactions may occur during pemetinib treatment, such as hyperphosphatemia, joint pain, etc., most adverse reactions can be controlled. No treatment-related deaths occurred during clinical trials.